* PainReform Ltd PRFX.OQ PRFX.O is expected to report
resultson August 8 (estimated) for the period ending June
30 2024
*
* LSEG's mean analyst estimate for PainReform Ltd is for a
loss
of $1.04 per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for PainReform
Ltd is
$2.00, above its last closing price of $0.33.
This summary was machine generated August 6 at 12:50 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)